Pembrolizumab/Vibostolimab

帕博利珠单抗/维博利单抗

Report date: 2026/05/13 20:02:10

Base Information

Drug NamePembrolizumab/Vibostolimab
Drug Alias NameCoformulation pembrolizumab/vibostolimabAnti-LAG-3/anti-TIGIT mAbMK-7684A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersT cell immunoglobulin and ITIM domains inhibitors
TargetsProgrammed cell death protein 1T cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[47] 
CombinationsYes PembrolizumabVibostolimab
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMsd Ireland (Carlow)Merck Sharp & Dohme CorpMerck Sharp & Dohme LLC +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[18] 
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A